Low-dose emicizumab for more equitable access to prophylaxis in resource limited countries.

Mannucci, Pier Mannuccio;Hermans, Cédric
(2024) Haemophilia (Print) — Vol. 30, n° 3, p. 575-576 (2024)

Files

2024_Mannucci_Haemophilia_Ab.pdf
  • Open Access
  • Adobe PDF
  • 197.69 KB
Download

Details

Authors
Abstract
This bispecific monoclonal antibody that mimics the coagulant activity of factor VIII (FVIII) has become a true game-changer in the management of haemophilia A (HA), making bleeding prophylaxis by subcutaneous injections a reality for all age groups, all degrees of FVIII deficiency and, most importantly, also for patients with FVIII inhibitors. [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Mannucci, P. M., & Hermans, C. (2024). Low-dose emicizumab for more equitable access to prophylaxis in resource limited countries. Haemophilia (Print), 30(3), 575-576. https://doi.org/10.1111/hae.14968 (Original work published 2024)